



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BioMark Receives US Trading Symbol BMKDF from FINRA and Commences Trading in the USA

Vancouver, British Columbia – (January 14, 2014) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX, FSE: 20B) is pleased to announce that shares of the Company have commenced trading on the OTC Pink Sheets under the symbol BMKDF.

Rashid Ahmed, President and CEO states: “This is the just the first step towards developing a shareholder base in the United States. The Company is fully reporting in Canada and is listed on the Canadian Securities Exchange as well as on the Frankfurt Stock Exchange. These multiple listings & quotation platforms will allow us to access a significantly larger base of interested American biopharma investors, providing enhanced liquidity and better valuation. We are delighted to work with Merriman Capital Inc., whose hard work and effort has allowed us to obtain our US trading symbol. The Company’s capital markets team will work to ensure that the Company meets additional requirements and take BioMark to the next level.”

About Merriman Capital, Inc.

Merriman Capital, Inc. is an [investment banking](#) firm providing equity and options execution services, market making, and differentiated research for high growth companies. The firm also provides capital raising, advisory, and M&A services. Merriman Capital, Inc. is a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR) and is the leading investment banking firm for OTCQX companies. For more information, please go to <http://www.merrimanco.com/>.

Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) <http://www.finra.org/> and the Securities Investor Protection Corporation (SIPC) <http://www.sipc.org/>.

About BioMark Diagnostics Inc.

BioMark is developing a proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-282-6567

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

The CSE has not reviewed, approved or disapproved the content of this press release.